Given this, a rapid and ultra-small volume-consuming determination of a combination of 2 of the most highly relevant and reliable sepsis biomarkers (combining a high specificity biomarker (PCT) with another of early diagnostic alarm/diagnostic readiness (IL-6)) using still disruptive technology such as MM is a considerable advance in the diagnosis of sepsis in preterm infants, which allows serial measurements in the first hours of the onset of symptoms to promptly initiate treatment in cases of true infection and avoid the use of antibiotics in the absence of sepsis. This evidence concerns the gene IL6 and infection.